EyePoint Pharmaceuticals (EYPT) Gains from Investment Securities: 2011-2019
Historic Gains from Investment Securities for EyePoint Pharmaceuticals (EYPT) over the last 7 years, with Dec 2019 value amounting to -$95,000.
- EyePoint Pharmaceuticals' Gains from Investment Securities was N/A to -$95,000 in Q4 2019 from the same period last year, while for Dec 2019 it was $694,000, marking a year-over-year change of. This contributed to the annual value of $17.5 million for FY2024, which is 10281.07% up from last year.
- As of Q4 2019, EyePoint Pharmaceuticals' Gains from Investment Securities stood at -$95,000, which was down 575.00% from $20,000 recorded in Q1 2019.
- In the past 5 years, EyePoint Pharmaceuticals' Gains from Investment Securities registered a high of $6.5 million during Q2 2018, and its lowest value of -$95,000 during Q4 2019.
- In the last 3 years, EyePoint Pharmaceuticals' Gains from Investment Securities had a median value of $1.4 million in 2018 and averaged $3.2 million.
- In the last 5 years, EyePoint Pharmaceuticals' Gains from Investment Securities spiked by 112,173.72% in 2015 and then tumbled by 98.55% in 2019.
- EyePoint Pharmaceuticals' Gains from Investment Securities (Quarterly) stood at $5.1 million in 2015, then grew by 19.29% to $6.1 million in 2016, then tumbled by 80.93% to $1.2 million in 2017, then soared by 459.00% to $6.5 million in 2018, then crashed by 98.55% to -$95,000 in 2019.
- Its last three reported values are -$95,000 in Q4 2019, $20,000 for Q1 2019, and $6.5 million during Q3 2018.